← Back to Search

Glucagon-like peptide-1 (GLP-1) receptor agonist

Liraglutide for Parkinson's Disease

Phase 2
Waitlist Available
Led By Michele Tagliati, MD
Research Sponsored by Cedars-Sinai Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline (week 0) to end of maintenance period (up to 54 weeks)
Awards & highlights

Study Summary

This study is evaluating whether a drug called liraglutide can improve symptoms of Parkinson's disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline (week 0) to end of maintenance period (up to 54 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline (week 0) to end of maintenance period (up to 54 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During "OFF" Time From Baseline to the End of Double-Blind Maintenance Period
Change in the Mattis Dementia Rating Scale (DRS-2) From Baseline to the End of Double-Blind Maintenance Period
Change in the Non-Motor Symptoms Scale (NMSS) Total Score From Baseline to the End of the Double-Blind Maintenance Period
Secondary outcome measures
Change in The Parkinson's Disease Questionnaire (PDQ-39) From Baseline to the End of Double-Blind Maintenance Period
Change in the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Index From Baseline to the End of Maintenance Period
Change in the Unified Parkinson's Disease Rating Scale Total Score From Baseline to the End of Double-Blind Maintenance Period

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: LiraglutideActive Control1 Intervention
Liraglutide 6 mg/ml (Novo Nordisk A/S) will be self-administered subcutaneously once daily at a maximum dose of 1.8 mg after a 2 week titration schedule.
Group II: PlaceboPlacebo Group1 Intervention
Placebo will be self-administered subcutaneously once daily according to the same schedule.

Find a Location

Who is running the clinical trial?

The Cure Parkinson's TrustUNKNOWN
2 Previous Clinical Trials
43 Total Patients Enrolled
Novo Nordisk A/SIndustry Sponsor
1,513 Previous Clinical Trials
2,414,966 Total Patients Enrolled
Cedars-Sinai Medical CenterLead Sponsor
499 Previous Clinical Trials
164,794 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety and Efficacy of Liraglutide in Parkinson's Disease
Michele Tagliati, MD 2017. "Safety and Efficacy of Liraglutide in Parkinson's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02953665.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top